About Polyneuron
Polyneuron is a company based in Basel (Switzerland) founded in 2014. It operates as a B2B. Polyneuron has raised $44.36 million across 6 funding rounds from investors including Zurcher Kantonalbank, Sofinnova Partners and NEA. Polyneuron offers products and services including PN-1007, PN-1018, PN-032, and PN-056. Polyneuron operates in a competitive market with competitors including BeiGene, Serum Institute of India, Vir Biotechnology, BioNTech and Harmony Biosciences, among others.
- Headquarter Basel, Switzerland
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Polyneuron Pharmaceuticals Ag
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$44.36 M (USD)
in 6 rounds
-
Latest Funding Round
$1.3 M (USD), Grant
Apr 14, 2021
-
Investors
Zurcher Kantonalbank
& 6 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Polyneuron
Polyneuron offers a comprehensive portfolio of products and services, including PN-1007, PN-1018, PN-032, and PN-056. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Treats anti-MAG neuropathy by eliminating autoantibodies
Targets antibodies for Guillain-Barré Syndrome and Multifocal Motor Neuropathy
Developed for ABO-incompatible organ transplantation
Supports ABO-incompatible stem cell transplantation
Unlock access to complete
Unlock access to complete
Funding Insights of Polyneuron
Polyneuron has successfully raised a total of $44.36M across 6 strategic funding rounds. The most recent funding activity was a Grant round of $1.3 million completed in April 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 6
- Last Round Grant — $1.3M
-
First Round
First Round
(02 Jun 2015)
- Investors Count 7
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr, 2021 | Amount | Grant - Polyneuron | Valuation |
investors |
|
| Sep, 2020 | Amount | Series A - Polyneuron | Valuation | Sofinnova Partners | |
| Mar, 2019 | Amount | Series A - Polyneuron | Valuation | New Enterprise Associates , Sofinnova Partners |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Polyneuron
Polyneuron has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include Zurcher Kantonalbank, Sofinnova Partners and NEA. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Sofinnova Partners is focused on life sciences and healthcare investments.
|
Founded Year | Domain | Location | |
|
Venture capital investments are offered to startups by NEA.
|
Founded Year | Domain | Location | |
|
Late-stage life sciences investments are managed via VC and PE.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Polyneuron
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Polyneuron
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Polyneuron Comparisons
Competitors of Polyneuron
Polyneuron operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BeiGene, Serum Institute of India, Vir Biotechnology, BioNTech and Harmony Biosciences, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Vaccines and immuno-biological drugs for infectious diseases are manufactured.
|
|
| domain | founded_year | HQ Location |
Developer of therapeutics for the treatment of infectious diseases
|
|
| domain | founded_year | HQ Location |
Immunotherapeutics for cancer and other diseases are developed.
|
|
| domain | founded_year | HQ Location |
Developer of therapeutics for rare neurological diseases
|
|
| domain | founded_year | HQ Location |
T-cell and antibody-based therapeutics are developed via single-cell sequencing platforms.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Polyneuron
Frequently Asked Questions about Polyneuron
When was Polyneuron founded?
Polyneuron was founded in 2014 and raised its 1st funding round 1 year after it was founded.
Where is Polyneuron located?
Polyneuron is headquartered in Basel, Switzerland. It is registered at Basel, Basel-stadt, Switzerland.
Is Polyneuron a funded company?
Polyneuron is a funded company, having raised a total of $44.36M across 6 funding rounds to date. The company's 1st funding round was a Series A of $22.62M, raised on Jun 02, 2015.
What does Polyneuron do?
Polyneuron Pharmaceuticals, based in Basel, Switzerland, develops novel therapies for autoimmune diseases. Using the Antibody-Catch platform, they create injectable glycopolymers that selectively eliminate pathological autoantibodies while preserving the immune system. The company focuses on drug discovery and clinical trials for conditions like anti-MAG neuropathy and Guillain-Barré Syndrome, aiming to address unmet medical needs through targeted treatments.
Who are the top competitors of Polyneuron?
Polyneuron's top competitors include BeiGene, BioNTech and Harmony Biosciences.
What products or services does Polyneuron offer?
Polyneuron offers PN-1007, PN-1018, PN-032, and PN-056.
Who are Polyneuron's investors?
Polyneuron has 7 investors. Key investors include Zurcher Kantonalbank, Sofinnova Partners, NEA, HBM Partners, and EVA.